Related references
Note: Only part of the references are listed.New Drug Delivery Systems in Inflammatory Bowel Disease: MMX™ and Tailored Delivery to the Gut
G. Fiorino et al.
CURRENT MEDICINAL CHEMISTRY (2010)
Rising Incidence of Inflammatory Bowel Disease Among Children: A 12-year Study
Hoda M. Malaty et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2010)
Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody
N. Pullen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Advances in the pathogenesis and treatment of IBD
Nicholas A. Braus et al.
CLINICAL IMMUNOLOGY (2009)
Engineering design and molecular dynamics of mucoadhesive drug delivery systems as targeting agents
Laura Serra et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2009)
pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model
Abdallah Makhof et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2009)
Biological Therapies for Inflammatory Bowel Diseases
Paul Rutgeerts et al.
GASTROENTEROLOGY (2009)
Amelioration of Colitis by Genetically Engineered Murine Regulatory T Cells Redirected by Antigen-Specific Chimeric Receptor
Eran Elinav et al.
GASTROENTEROLOGY (2009)
Effect of Extended MMX Mesalamine Therapy for Acute, Mild-to-Moderate Ulcerative Colitis
Michael A. Kamm et al.
INFLAMMATORY BOWEL DISEASES (2009)
Intestinal Barrier Dysfunction in Inflammatory Bowel Diseases
Michael A. McGuckin et al.
INFLAMMATORY BOWEL DISEASES (2009)
The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-alpha(4)beta(7) Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
Dulce Soler et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Delivery of Human Immunodeficiency Virus Vaccine Vectors to the Intestine Induces Enhanced Mucosal Cellular Immunity
Lingshu Wang et al.
JOURNAL OF VIROLOGY (2009)
Monoclonal anti body-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project
Kenneth R. Carson et al.
LANCET ONCOLOGY (2009)
Transferrin as a Luminal Target for Negatively Charged Liposomes in the Inflamed Colonic Mucosa
Boaz Tirosh et al.
MOLECULAR PHARMACEUTICS (2009)
Golimumab
Dimitrios A. Pappas et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Selective Adhesion of Nanoparticles to Inflamed Tissue in Gastric Ulcers
Saad Hasani et al.
PHARMACEUTICAL RESEARCH (2009)
Basiliximab and Infliximab for the Treatment of Steroid-Refractory Crohn's Disease
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Multi-matrix system mesalamine: To use or not to use
Pramodini B. Kale-Pradhan et al.
ANNALS OF PHARMACOTHERAPY (2008)
Systems for region selective drug delivery in the gastrointestinal tract: biopharmaceutical considerations
Leonid Kagan et al.
EXPERT OPINION ON DRUG DELIVERY (2008)
Target-specific drug release to the colon
Sanjay K. Jain et al.
EXPERT OPINION ON DRUG DELIVERY (2008)
A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
William J. Sandborn et al.
GASTROENTEROLOGY (2008)
Role of Probiotic Therapy in IBD
Kim Isaacs et al.
INFLAMMATORY BOWEL DISEASES (2008)
Alternative drug delivery approaches for the therapy of inflammatory bowel disease
Yvette Meissner et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
Role of the intestinal barrier in inflammatory bowel disease
Mike G. Laukoetter et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Colon Targeted Drug Delivery Systems -An Overview
P. Kumar et al.
Current Drug Delivery (2008)
The genetics and immunopathogenesis of inflammatory bowel disease
Judy H. Cho
NATURE REVIEWS IMMUNOLOGY (2008)
Gene delivery to intestinal epithelial cells in vitro and in vivo with recombinant adeno-associated virus types 1, 2 and 5
Steven Polyak et al.
DIGESTIVE DISEASES AND SCIENCES (2008)
Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis
J. M. Rhodes et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Manipulation of Intestinal Microbial Flora for Therapeutic Benefit in Inflammatory Bowel Diseases: Review of Clinical Trials of Probiotics, Prebiotics and Synbiotics
Debra Heilpern et al.
REVIEWS ON RECENT CLINICAL TRIALS (2008)
A phase I study of visilizumab a humanized anti-CD3, monoclonal antibody, in severe steroid-refractory ulcerative colitis
Scott Plevy et al.
GASTROENTEROLOGY (2007)
Certolizumab pegol for the treatment of Crohn's disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE trial
Stephan R. Targan et al.
GASTROENTEROLOGY (2007)
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease
Ann Corken Mackey et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2007)
Mucoadhesion mechanism of chitosan and thiolated chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles
Irene Bravo-Osuna et al.
BIOMATERIALS (2007)
Restituting intestinal epithelial cells exhibit increased transducibility by adenoviral vectors
Filippos Kesisoglou et al.
JOURNAL OF GENE MEDICINE (2006)
Interleukin 6: from bench to bedside
Norihiro Nishimoto et al.
NATURE CLINICAL PRACTICE RHEUMATOLOGY (2006)
Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-α accounts for a favourable clinical response in selected cases:: A pilot study
Corrado R. Asteria et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2006)
Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules
Kazuhiko Nakamura et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2006)
Incidence of inflammatory bowel disease in Finnish children, 1987-2003
Pieta Turunen et al.
INFLAMMATORY BOWEL DISEASES (2006)
Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease
D. W. Hommes et al.
GUT (2006)
Nanoparticles in inflammatory bowel disease: Particle targeting versus pH-sensitive delivery
Yvette Meissner et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2006)
Increasing incidences of inflammatory bowel disease and decreasing surgery rates in copenhagen city and county, 2003-2005: A population-based study from the Danish crohn colitis database
Ida Vind et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
Drug insight:: Antagonists of tumor-necrosis factor-α in the treatment of inflammatory bowel disease
JT Chang et al.
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY (2006)
A phase I trial with Transgenic bacteria expressing interleukin-10 in Crohn's disease
Henri Braat et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Natalizumab induction and maintenance therapy for Crohn's disease
WJ Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Chimeric Ad5 vectors expressing the short fiber of Ad41 show reduced affinity for human intestinal epithelium
Filippos Kesisoglou et al.
MOLECULAR PHARMACEUTICS (2005)
Liposomal formulations of inflammatory bowel disease drugs:: Local versus systemic drug delivery in a rat model
F Kesisoglou et al.
PHARMACEUTICAL RESEARCH (2005)
Brief report - Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
G Van Assche et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease
A Kasran et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Increased transduction of human intestinal epithelial cells by adenoviral vectors in inflammatory bowel disease
P Schmiedlin-Ren et al.
INFLAMMATORY BOWEL DISEASES (2005)
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease
GR Lichtenstein et al.
GASTROENTEROLOGY (2005)
Local prevention of oxidative stress in the intestinal epithelium of the rat by adhesive liposomes of superoxide dismutase and tempamine
Tareq Taha Jubeh et al.
MOLECULAR PHARMACEUTICS (2005)
Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide
RN Fedorak et al.
ADVANCED DRUG DELIVERY REVIEWS (2005)
New oral delivery systems for treatment of inflammatory bowel disease
DR Friend
ADVANCED DRUG DELIVERY REVIEWS (2005)
Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease
U Klotz et al.
ADVANCED DRUG DELIVERY REVIEWS (2005)
Biologic therapy for inflammatory bowel disease
S Ardizzone et al.
DRUGS (2005)
Probiotics and the management of inflammatory bowel disease
RN Fedorak et al.
INFLAMMATORY BOWEL DISEASES (2004)
Lectin-mediated drug targeting: history and applications
C Bies et al.
ADVANCED DRUG DELIVERY REVIEWS (2004)
The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery
F Gabor et al.
ADVANCED DRUG DELIVERY REVIEWS (2004)
Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes
TT Jubeh et al.
PHARMACEUTICAL RESEARCH (2004)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Optimizing anti-TNF treatment in inflammatory bowel disease
P Rutgeerts et al.
GASTROENTEROLOGY (2004)
Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo
HS Sakhalkar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Oral budesonide in the management of Crohn's disease
KN Hofer
ANNALS OF PHARMACOTHERAPY (2003)
The immunological and genetic basis of inflammatory bowel disease
G Bouma et al.
NATURE REVIEWS IMMUNOLOGY (2003)
Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10
L Steidler et al.
NATURE BIOTECHNOLOGY (2003)
Gene transfer approaches for the treatment of inflammatory bowel disease
S Wirtz et al.
GENE THERAPY (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
New cytokine delivery system using gelatin microspheres containing interleukin-10 for experimental inflammatory bowel disease
H Nakase et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa
A Lamprecht et al.
PHARMACEUTICAL RESEARCH (2001)
Colonic drug delivery: Prodrug approach
VR Sinha et al.
PHARMACEUTICAL RESEARCH (2001)
A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis
MW Rudolph et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2001)
Evaluation of an intestinal pressure-controlled colon delivery capsules prepared by a dipping method
YI Jeong et al.
JOURNAL OF CONTROLLED RELEASE (2001)
Drug targeting
VP Torchilin
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2000)
Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis
G Frieri et al.
GUT (2000)
Treatment of murine colitis by Lactococcus lactis secreting interleukin-10
L Steidler et al.
SCIENCE (2000)
Transfer of interleukin-4 and interleukin-10 in patients with severe inflammatory bowel disease of the rectum
MA Rogy et al.
HUMAN GENE THERAPY (2000)
Apical gene transfer into quiescent human and canine polarized intestinal epithelial cells by lentivirus vectors
J Seppen et al.
JOURNAL OF VIROLOGY (2000)
Retargeting the coxsackievirus and adenovirus receptor to the apical surface of polarized epithelial cells reveals the glycocalyx as a barrier to adenovirus-mediated gene transfer
RJ Pickles et al.
JOURNAL OF VIROLOGY (2000)
Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation:: Evidence in Crohn disease and experimental colitis in vivo
R Atreya et al.
NATURE MEDICINE (2000)
Interleukin 10 gene transfer prevents experimental colitis in rats
G Barbara et al.
GUT (2000)
Molecular aspects of muco- and bioadhesion: Tethered structures and site-specific surfaces
YB Huang et al.
JOURNAL OF CONTROLLED RELEASE (2000)
Share Paper
